NATI genotypes do not predict response to mesalamine in patients with ulcerative colitis

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 3, 2008, Pages 259-265

  Hausmann, Martin ^a   Paul, G ^b   Menzel, K ^b   Brunner Ploss, R ^b   Falk, W ^b   Scholmerich J ^b   Herfarth, H ^c   Rogler, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Intestinal complications; Ulcerative colitis

Indexed keywords

ACYLTRANSFERASE; DNA; GLUCOCORTICOID; MERCAPTOPURINE; MESALAZINE; ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; N ACETYLTRANSFERASE 1; N-ACETYLTRANSFERASE 1; NONSTEROID ANTIINFLAMMATORY AGENT;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEART DISEASE; HEART PAIN; HEMOLYSIS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; POLYMERASE CHAIN REACTION; PREDICTION; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SIDE EFFECT; STOMACH PAIN; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; GENETIC PREDISPOSITION; GENETICS; GERMANY; METHODOLOGY; OUTCOME ASSESSMENT; PREVALENCE; STATISTICS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYLAMINE N-ACETYLTRANSFERASE; COLITIS, ULCERATIVE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; ISOENZYMES; MESALAMINE; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; TREATMENT OUTCOME;

EID: 41949112256     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963673     Document Type: Article

References (34)

1. Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy 1994; 14: 385-398
2. Easterbrook J, Armstrong G, Bayless TM et al. Pharmacogenetics of 5ASA metabolism in IBD patients: Preliminary report of variation in N-acetyltransferase polymorphisms and 5ASA metabolism rates in mucosal biopsies. Annual Meeting of American Gastroenterological Association. New Orleans Philadelphia: W B Saunder Company, 1998
3. Zhou SY, Fleisher D, Pao LH et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999; 27 (4): 479-485
4. Jenne JW. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J Clin Invest 1965; 44 (12): 1992-2002
5. Ilett KF, Ingram DM, Carpenter DS et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 1994; 47 (5): 914-917
6. Hein DW, Doll MA, Rustan TD et al. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55 (16): 3531-3536
7. Bell DA, Badawi AF, Lang NP et al. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55 (22): 5226-5229
8. Windmill KF, Gaedigk A, Hall PM et al. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 2000; 54 (1): 19-29
9. Debiec-Rychter M, Land SJ, King CM. Histological localization of acetyltransferases in human tissue. Cancer Lett 1999; 143 (2): 99-102
10. Hickman D, Pope J, Patil SD et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998; 42 (3): 402-409
11. Christensen LA, Fallingborg J, Abildgaard K et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4 (5): 523-533
12. Larouche J, Morais J, Picard M et al. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment Pharmacol Ther 1995; 9 (3): 315-320
13. Layer PH, Goebell H, Keller J et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 1427-1433
14. Yu DK, Morrill B, Eichmeier LS et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur J Clin Pharmacol 1995; 48 (3-4): 273-277
15. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265 (22): 12757-12760
16. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C 190T and G560A mutations. Pharmacogenetics 1998; 8 (1): 67-72
17. Bruhn C, Brockmoller J, Cascorbi I et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58 (11): 1759-1764
18. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem Pharmacol 1998; 55 (3): 361-366
19. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1993; 3 (4): 209-212
20. Hein DW, Rustan TD, Ferguson RJ et al. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994; 68 (2): 129-133
21. Allgayer H, Ahnfelt NO, Kruis W et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97 (1): 38-41
22. Vatsis KP, Weber WW, Bell DA et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5 (1): 1-17
23. Grant DM, Blum M, Beer M et al. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39 (2): 184-191
24. Ozawa S, Abu-Zeid M, Kawakubo Y et al. Monomorphic and polymorphic isozymes of arylamine N-acetyltransferases in hamster liver: purification of the isozymes and genetic basis of N-acetylation polymorphism. Carcinogenesis 1990; 11 (12): 2137-2144
25. Hughes NC, Janezic SA, McQueen KL et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8 (1): 55-66
26. Schreiber S, Hamling J, Zehnter E et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997; 40 (6): 761-766
27. Ricart E, Taylor WR, Loftus EV et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002; 97 (7): 1763-1768
28. Hein DW, McQueen CA, Grant DM et al. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 2000; 28 (12): 1425-1432
29. Sim E, Payton M, Noble M et al. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum Mol Genet 2000; 9 (16): 2435-2441
30. Deitz AC, Doll MA, Hein DW. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 1997; 253 (2): 219-224
31. Rasmussen SN, Bondesen S, Hvidberg EF et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982; 83: 1062-1070
32. de Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 2000; 58 (2): 288-299
33. Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9 (1): 29-42
34. Cascorbi I, Roots I, Brockmoller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001; 61 (13): 5051-5056